Georgia Anguera
Overview
Explore the profile of Georgia Anguera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
126
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vidal N, Climent M, Perez S, Mendez-Vidal M, Anguera G, Martinez Salas I, et al.
Clin Transl Oncol
. 2024 Oct;
PMID: 39369361
Introduction: The COVID-19 pandemic is a great burden worldwide, but its impact on patients with genitourinary cancer (GUC) is poorly characterized. This study aimed to characterize the clinical features and...
2.
Afferi L, Cimadamore A, Gallioli A, Pradere B, Mertens L, Marcq G, et al.
Eur Urol
. 2024 Sep;
87(1):1-4.
PMID: 39266382
The European Association of Urology (EAU), National Comprehensive Cancer Network, and European Society for Medical Oncology guidelines recommend PD-L1 and FGFR testing for patients with locally advanced bladder cancer or...
3.
Day E, Gavira J, Tapia J, Anguera G, Maroto P
Eur Urol Focus
. 2024 Jun;
10(2):227-230.
PMID: 38849276
Approximately 25% of bladder cancers exhibit variant histology, an updated term used in the 2022 World Health Organization histological classification of bladder cancer. These variant histologies differ by molecular pattern...
4.
Anguera G, Mulet M, Zamora C, Osuna-Gomez R, Barba A, Sullivan I, et al.
Biomedicines
. 2024 May;
12(5).
PMID: 38790920
PD-(L)1 inhibitors are part of the treatment strategy for non-small cell lung cancer (NSCLC) although its efficacy is limited to certain patients. Our study aimed to identify patients who might...
5.
Alserawan L, Mulet M, Anguera G, Riudavets M, Zamora C, Osuna-Gomez R, et al.
Cancers (Basel)
. 2024 May;
16(9).
PMID: 38730712
Immune checkpoint inhibitors (ICI) have the potential to trigger unpredictable immune-related adverse events (irAEs), which can be severe. The underlying mechanisms of these events are not fully understood. As PD-L1...
6.
Gavira J, Tapia J, Romano A, Anguera G, Aguado M, Piedra A, et al.
Clin Transl Oncol
. 2024 May;
26(10):2749-2753.
PMID: 38722534
Purpose: We evaluated the prevalence of homologous recombination deficiencies (HRD) to determine the efficacy of different techniques and clinical characteristics of patients. Methods: This retrospective study included patients with metastatic...
7.
Tapia J, Bosma F, Gavira J, Sanchez S, Molina M, Sanz-Beltran J, et al.
Clin Genitourin Cancer
. 2024 Mar;
22(3):102047.
PMID: 38430859
Introduction: Metastatic urothelial carcinoma (mUC) is a lethal disease with limited treatment options. We aimed to compare the treatment patterns and outcomes of patients with mUC who were treated before...
8.
Tapia J, Gavira J, Anguera G, Sanchez S, Romano A, Bosma F, et al.
Clin Transl Oncol
. 2024 Feb;
26(7):1798-1803.
PMID: 38421563
Purpose: To describe the incidences of hypogonadism, hypertension, and dyslipidaemia in patients with stage 1 seminoma (S1S) testicular cancer (TC) treated with a risk-adapted strategy. Methods: A retrospective analysis from...
9.
Canto E, Anguera G, Jimenez N, Mellado B, Ramirez O, Mariscal A, et al.
Diagnostics (Basel)
. 2023 Jul;
13(13).
PMID: 37443615
(1) Background: Prostate cancer is the second most common cancer in men, with androgen suppression as the standard treatment. Despite initially responding to castration, most metastatic prostate cancer patients eventually...
10.
Roldan-Romero J, Valdivia C, Santos M, Lanillos J, Maroto P, Anguera G, et al.
Int J Cancer
. 2023 Jun;
153(6):1300-1312.
PMID: 37260183
Mammalian target of rapamycin (mTOR) is a central regulator of mammalian metabolism and physiology. Aberrant hyperactivation of the mTOR pathway promotes tumor growth and metastasis, and can also promote tumor...